


Bezafibrate PK Fact Sheet

Prepared March 2026

Page 1 of 2

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

Details

Generic Name	Bezafibrate
Trade Name	Bezalip®, Cedur®, available as generic products
Class	PBC agents
Molecular Weight	361.8
Structure	

Summary of Key Pharmacokinetic Parameters

Linearity/non-linearity	Not reported No accumulation (200 mg, every 8 hours, in healthy volunteers) ¹
Steady state	32 h ¹
Plasma half-life	1-2 h
C _{max}	9.1 mg/L (200 mg, every 8 hours, in healthy volunteers) ¹
C _{min}	1 mg/L (200 mg, three times daily, in healthy volunteers) ¹
AUC	23.8 mg/L • h (200 mg, every 8 hours, in healthy volunteers) ¹
Bioavailability	Not reported.
Absorption	T _{max} is 1-2 h (200 mg single dose in healthy volunteers). Bezafibrate should be taken after food.
Protein Binding	~95%
Volume of Distribution	17 L
Renal Clearance	95% dose recovered in urine.
Renal Impairment	Dose modification is required in patients with renal impairment. Refer to product label for dose adjustment according to serum creatinine and creatinine clearance. Bezafibrate is contraindicated in nephrotic syndrome, severe renal impairment, and in patients undergoing kidney dialysis.
Hepatic Impairment	Coadministration is contraindicated in decompensated liver disease. ²

Metabolism and Distribution

Metabolized by	Not reported
Inducer of	Not reported
Inhibitor of	OAT1, OAT3 ³
Transported by	OAT1, OAT3 ³

Italics denotes effect seen in vitro/animal studies only

Bezafibrate PK Fact Sheet

Prepared March 2026

Page 2 of 2

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

References

Unless otherwise stated (see below), information is from:

Bezafibrate Summary of Product Characteristics, Teva UK Limited, April 2024.

1. Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia. JP Monk & PA Todd. *Drugs*, 1987, 33(6):539-76.
2. Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases. KD Lindor, C Bowlus, J Boyer et al. *Hepatology*, 2022, 75(4):1012-23.
3. Bezafibrate-mizoribine interaction: Involvement of organic anion transporters OAT1 and OAT3 in rats, Y Feng, C Wang, Q Liu et al. *Eur J Pharm Sci*, 2016, 81:119-28.